JP2018508188A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508188A5 JP2018508188A5 JP2017536356A JP2017536356A JP2018508188A5 JP 2018508188 A5 JP2018508188 A5 JP 2018508188A5 JP 2017536356 A JP2017536356 A JP 2017536356A JP 2017536356 A JP2017536356 A JP 2017536356A JP 2018508188 A5 JP2018508188 A5 JP 2018508188A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- region
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021038857A JP7177317B2 (ja) | 2015-01-08 | 2021-03-11 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| JP2022162493A JP7596342B2 (ja) | 2015-01-08 | 2022-10-07 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2015/050276 | 2015-01-08 | ||
| PCT/EP2015/050276 WO2015104346A1 (en) | 2014-01-09 | 2015-01-08 | Humanized or chimeric cd3 antibodies |
| DKPA201500413 | 2015-07-15 | ||
| DKPA201500412 | 2015-07-15 | ||
| DKPA201500413 | 2015-07-15 | ||
| DKPA201500412 | 2015-07-15 | ||
| DKPA201500416 | 2015-07-16 | ||
| DKPA201500416 | 2015-07-16 | ||
| DKPA201500415 | 2015-07-16 | ||
| DKPA201500415 | 2015-07-16 | ||
| PCT/EP2016/050296 WO2016110576A1 (en) | 2015-01-08 | 2016-01-08 | Bispecific antibodies against cd3 and cd20 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021038857A Division JP7177317B2 (ja) | 2015-01-08 | 2021-03-11 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508188A JP2018508188A (ja) | 2018-03-29 |
| JP2018508188A5 true JP2018508188A5 (enExample) | 2019-02-14 |
| JP6853176B2 JP6853176B2 (ja) | 2021-03-31 |
Family
ID=56355550
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536356A Active JP6853176B2 (ja) | 2015-01-08 | 2016-01-08 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| JP2021038857A Active JP7177317B2 (ja) | 2015-01-08 | 2021-03-11 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| JP2022162493A Active JP7596342B2 (ja) | 2015-01-08 | 2022-10-07 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021038857A Active JP7177317B2 (ja) | 2015-01-08 | 2021-03-11 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| JP2022162493A Active JP7596342B2 (ja) | 2015-01-08 | 2022-10-07 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10544220B2 (enExample) |
| EP (2) | EP4678661A3 (enExample) |
| JP (3) | JP6853176B2 (enExample) |
| KR (3) | KR20240148942A (enExample) |
| CN (2) | CN107660214B (enExample) |
| AU (3) | AU2016205967B2 (enExample) |
| CA (1) | CA2973159A1 (enExample) |
| EA (1) | EA201791554A1 (enExample) |
| IL (3) | IL289946B2 (enExample) |
| MX (2) | MX391279B (enExample) |
| SG (1) | SG11201705496SA (enExample) |
| UA (1) | UA120286C2 (enExample) |
| WO (1) | WO2016110576A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3434767T (pt) * | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| HUE048722T2 (hu) | 2013-07-05 | 2020-08-28 | Genmab As | Humanizált vagy kiméra CD3 ellenanyagok |
| KR102225489B1 (ko) | 2013-12-17 | 2021-03-10 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| SG11201701627PA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Anti-cll-1 antibodies and immunoconjugates |
| EP3916018A1 (en) | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| ES2957567T3 (es) | 2015-06-16 | 2024-01-22 | Hoffmann La Roche | Anticuerpos humanizados y de afinidad madurada contra FcRH5 y procedimientos de uso |
| AU2016293073B2 (en) | 2015-07-15 | 2022-12-22 | Genmab A/S | Humanized or chimeric CD3 antibodies |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| CA3059010A1 (en) * | 2016-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| EP3252078A1 (en) * | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| JP7083819B2 (ja) * | 2016-09-30 | 2022-06-13 | セントレ ナショナル デ ラ レセルシュ シャンティフィク | 細胞マーカー |
| US11466094B2 (en) * | 2016-11-15 | 2022-10-11 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
| KR102692708B1 (ko) | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
| EP3661555B1 (en) | 2017-08-01 | 2025-04-16 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| WO2019025545A1 (en) * | 2017-08-04 | 2019-02-07 | Genmab A/S | BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE |
| EP3668898B1 (en) | 2017-08-14 | 2023-07-05 | MorphoSys AG | Humanized antibodies for cd3 |
| CN107501412A (zh) * | 2017-10-11 | 2017-12-22 | 深圳精准医疗科技有限公司 | 突变型双特异性抗体及其应用 |
| CN118772287A (zh) | 2018-02-08 | 2024-10-15 | 豪夫迈·罗氏有限公司 | 双特异性抗原结合分子和使用方法 |
| JP7326345B2 (ja) * | 2018-02-09 | 2023-08-15 | ジェンマブ アクティーゼルスカブ | Ｃｄ３及びｃｄ２０に対する二重特異性抗体を含む医薬組成物及びそれらの使用 |
| CA3093330A1 (en) * | 2018-03-14 | 2019-09-19 | Novimmune Sa | Anti-cd3 epsilon antibodies and methods of use thereof |
| EP3569617A1 (en) * | 2018-05-18 | 2019-11-20 | Trion Research GmbH | Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases |
| CN110540593B (zh) * | 2018-05-29 | 2022-05-17 | 上海药明生物技术有限公司 | 新型的抗cd3/抗cd20双特异性抗体 |
| WO2019244107A1 (en) * | 2018-06-21 | 2019-12-26 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109836502B (zh) * | 2018-11-12 | 2021-09-07 | 浙江大学 | 一种双特异性抗体及其应用 |
| US12463463B2 (en) | 2019-01-28 | 2025-11-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| WO2020168555A1 (zh) * | 2019-02-22 | 2020-08-27 | 武汉友芝友生物制药有限公司 | Cd3抗原结合片段及其应用 |
| EP3969907B1 (en) * | 2019-05-13 | 2025-09-24 | F. Hoffmann-La Roche AG | Interference-suppressed pharmacokinetic immunoassay |
| CN110551221B (zh) * | 2019-07-02 | 2021-03-05 | 广州爱思迈生物医药科技有限公司 | 一种双特异性抗体及其制备方法与应用 |
| UA128416C2 (uk) * | 2019-08-15 | 2024-07-03 | Генмаб А/С | Фармацевтичні композиції, які містять біспецифічні антитіла проти cd3 і cd20, та їх застосування |
| CN111100204B (zh) * | 2019-11-26 | 2022-03-11 | 山东立菲生物产业有限公司 | 靶向cd20的抗体、其制备方法和应用 |
| PE20221511A1 (es) | 2019-12-13 | 2022-10-04 | Genentech Inc | Anticuerpos anti-ly6g6d y metodos de uso |
| EP4090377A1 (en) * | 2020-01-13 | 2022-11-23 | Synaffix B.V. | Conjugates of antibodies an immune cell engagers |
| CN113402612A (zh) * | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CA3168613A1 (en) * | 2020-03-18 | 2021-09-23 | Genmab A/S | Antibodies binding to b7h4 |
| CA3176436A1 (en) | 2020-05-08 | 2021-11-11 | Tahamtan Ahmadi | Bispecific antibodies against cd3 and cd20 |
| US11976120B2 (en) | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US10981996B1 (en) | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| CN112062855B (zh) * | 2020-08-26 | 2024-08-30 | 北京天诺健成医药科技有限公司 | 一种含有衔接器的药物治疗剂的开发和应用 |
| AU2021342343A1 (en) * | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| CN116406293A (zh) | 2020-09-10 | 2023-07-07 | 健玛保 | 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
| JP2023542291A (ja) * | 2020-09-10 | 2023-10-06 | ジェンマブ エー／エス | びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| US20240034812A1 (en) | 2020-09-10 | 2024-02-01 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| JP2023542289A (ja) | 2020-09-10 | 2023-10-06 | ジェンマブ エー／エス | 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| JP2023541858A (ja) * | 2020-09-10 | 2023-10-04 | ジェンマブ エー／エス | 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| CA3196539A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| IL302400A (en) | 2020-11-04 | 2023-06-01 | Genentech Inc | Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies |
| CA3196191A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| CN114656562B (zh) | 2020-12-23 | 2023-11-03 | 北京天广实生物技术股份有限公司 | 结合人和猴cd3的抗体及其应用 |
| SI4284512T1 (sl) | 2021-01-28 | 2025-06-30 | Regeneron Pharmaceuticals, Inc. | Sestavki in postopki za zdravljenje sindroma sproščanja citokinov |
| US20240139322A1 (en) * | 2021-03-10 | 2024-05-02 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods to reduce therapeutic t cell toxicity |
| CA3210971A1 (en) * | 2021-03-12 | 2022-09-15 | Bart-Jan DE KREUK | Non-activating antibody variants |
| AU2021443318A1 (en) | 2021-04-30 | 2023-09-07 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| WO2022241235A1 (en) | 2021-05-14 | 2022-11-17 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| MX2024008832A (es) | 2022-01-28 | 2024-07-25 | Genmab As | Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para tratar linfoma difuso de celulas b grandes. |
| WO2023144290A1 (en) | 2022-01-28 | 2023-08-03 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| US20250304689A1 (en) | 2022-04-13 | 2025-10-02 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| WO2023201291A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| CA3277013A1 (en) * | 2022-12-14 | 2024-06-20 | Evolveimmune Therapeutics, Inc. | BISPECIFIC ANTIBODY FUSION MOLECULES AND THEIR METHODS OF USE |
| IL322545A (en) | 2023-02-17 | 2025-10-01 | Regeneron Pharma | Induced NK cells responding to bispecific CD3/TAA antibodies |
| AU2024244733B2 (en) | 2023-03-31 | 2025-12-11 | AbelZeta Inc. | Bispecific chimeric antigen receptors targeting cd20 and bcma |
| US20240368297A1 (en) | 2023-04-13 | 2024-11-07 | Genmab A/S | Methods of treating lymphoma with bispecific antibodies against cd3 and cd20 |
| IL324480A (en) | 2023-05-15 | 2026-01-01 | Genmab As | Highly purified epcoritamab compositions |
| KR20260013467A (ko) | 2023-05-15 | 2026-01-28 | 젠맵 에이/에스 | Cd20 발현 b-세포 암을 치료하는 방법 |
| AU2024346729A1 (en) * | 2023-09-20 | 2026-03-19 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof |
| WO2025109119A1 (en) * | 2023-11-22 | 2025-05-30 | Priothera Sas | Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077A (en) | 1849-01-30 | Improved hinged claw-wrench | ||
| US835A (en) | 1838-07-12 | X i i i x | ||
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| CA2347067C (en) | 1998-03-31 | 2013-09-17 | Geron Corporation | Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer |
| DE60013773T2 (de) | 1999-02-03 | 2005-11-10 | Biosante Pharmaceuticals, Inc. | Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| US6713055B2 (en) | 2000-11-27 | 2004-03-30 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| CA2478011C (en) | 2002-03-01 | 2013-05-21 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
| PL216630B1 (pl) * | 2002-10-17 | 2014-04-30 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie |
| US20050100543A1 (en) | 2003-07-01 | 2005-05-12 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP1940881B1 (en) * | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| AU2006317242A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| GEP20135917B (en) | 2006-03-17 | 2013-09-10 | Biogen Idec Inc | Stabilized polypeptide compositions |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP2139924B1 (en) | 2007-03-29 | 2016-07-06 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| EP2170951A2 (en) * | 2007-05-31 | 2010-04-07 | Genmab A/S | Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering |
| US20100291023A1 (en) * | 2007-05-31 | 2010-11-18 | Genmab A/S | Method for extending the half-life of exogenous or endogenous soluble molecules |
| CA2689695A1 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals |
| ES2702087T3 (es) | 2007-06-21 | 2019-02-27 | Macrogenics Inc | Diacuerpos covalentes y sus usos |
| JP5592792B2 (ja) | 2007-09-26 | 2014-09-17 | ユセベ ファルマ ソシエテ アノニム | 二重特異性抗体の融合体 |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| AU2009299794B2 (en) * | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| SG172254A1 (en) | 2008-12-19 | 2011-07-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
| CN102448984A (zh) | 2009-03-27 | 2012-05-09 | 酶遗传学股份有限公司 | 使用包含抗体-受体组合的多特异性结合蛋白的组合物和方法 |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| PL2506871T3 (pl) | 2009-11-30 | 2017-03-31 | Janssen Biotech, Inc | Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi |
| MX2012006406A (es) | 2009-12-04 | 2012-07-25 | Genentech Inc | Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos. |
| SG181952A1 (en) | 2009-12-29 | 2012-07-30 | Emergent Product Dev Seattle | Heterodimer binding proteins and uses thereof |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| RU2608640C2 (ru) | 2010-08-16 | 2017-01-23 | Новиммун С.А. | Способы получения мультиспецифичных и мультивалентных антител |
| RU2013110876A (ru) | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
| RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| PT3434767T (pt) * | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| AU2012245116A1 (en) * | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| CN107827985A (zh) * | 2011-05-21 | 2018-03-23 | 宏观基因有限公司 | 能够与人和非人cd3结合的cd3结合分子 |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| PH12013502531A1 (en) | 2011-08-23 | 2014-01-20 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| HUE044633T2 (hu) | 2011-10-27 | 2019-11-28 | Genmab As | Heterodimer fehérjék elõállítása |
| DK2838917T3 (da) | 2012-04-20 | 2019-08-26 | Merus Nv | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler |
| AU2013285355A1 (en) * | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| ES2744267T3 (es) | 2012-11-21 | 2020-02-24 | Pharmabcine Inc | Anticuerpo de doble diana que se dirige a VEGFR-2 y DLL4, y composición farmacéutica que comprende el mismo |
| WO2014131711A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| CN110845618A (zh) | 2013-02-26 | 2020-02-28 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
| HUE048722T2 (hu) | 2013-07-05 | 2020-08-28 | Genmab As | Humanizált vagy kiméra CD3 ellenanyagok |
| US20160355588A1 (en) * | 2013-07-12 | 2016-12-08 | Zymeworks Inc. | Bispecific CD3 and CD19 Antigen Binding Constructs |
| KR102225489B1 (ko) * | 2013-12-17 | 2021-03-10 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| AU2015350075B2 (en) | 2014-11-17 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using CD3xCD20 bispecific antibody |
| EP3464370A1 (en) | 2016-06-01 | 2019-04-10 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
| EP3668898B1 (en) * | 2017-08-14 | 2023-07-05 | MorphoSys AG | Humanized antibodies for cd3 |
| CN116406293A (zh) * | 2020-09-10 | 2023-07-07 | 健玛保 | 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
-
2016
- 2016-01-08 UA UAA201708112A patent/UA120286C2/uk unknown
- 2016-01-08 CN CN201680014755.4A patent/CN107660214B/zh active Active
- 2016-01-08 MX MX2017008875A patent/MX391279B/es unknown
- 2016-01-08 US US15/541,594 patent/US10544220B2/en active Active
- 2016-01-08 IL IL289946A patent/IL289946B2/en unknown
- 2016-01-08 IL IL318350A patent/IL318350A/en unknown
- 2016-01-08 KR KR1020247032341A patent/KR20240148942A/ko active Pending
- 2016-01-08 WO PCT/EP2016/050296 patent/WO2016110576A1/en not_active Ceased
- 2016-01-08 KR KR1020247014333A patent/KR102712786B1/ko active Active
- 2016-01-08 CN CN202210117824.1A patent/CN114478792A/zh active Pending
- 2016-01-08 EP EP25189898.7A patent/EP4678661A3/en active Pending
- 2016-01-08 JP JP2017536356A patent/JP6853176B2/ja active Active
- 2016-01-08 AU AU2016205967A patent/AU2016205967B2/en active Active
- 2016-01-08 KR KR1020177021738A patent/KR102663073B1/ko active Active
- 2016-01-08 EA EA201791554A patent/EA201791554A1/ru unknown
- 2016-01-08 EP EP16700133.8A patent/EP3242682A1/en not_active Withdrawn
- 2016-01-08 SG SG11201705496SA patent/SG11201705496SA/en unknown
- 2016-01-08 CA CA2973159A patent/CA2973159A1/en active Pending
-
2017
- 2017-06-25 IL IL253166A patent/IL253166B/en unknown
- 2017-07-04 MX MX2022004082A patent/MX2022004082A/es unknown
-
2019
- 2019-12-04 US US16/702,996 patent/US20200199231A1/en active Pending
-
2021
- 2021-03-11 JP JP2021038857A patent/JP7177317B2/ja active Active
-
2022
- 2022-02-10 AU AU2022200871A patent/AU2022200871B2/en active Active
- 2022-10-07 JP JP2022162493A patent/JP7596342B2/ja active Active
-
2025
- 2025-08-07 AU AU2025213616A patent/AU2025213616A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508188A5 (enExample) | ||
| US10899842B2 (en) | 4-1BB binding proteins and uses thereof | |
| TWI508745B (zh) | ＴＮＦ－α結合蛋白 | |
| US8877194B2 (en) | TNF-α binding proteins | |
| CN102906113B (zh) | 治疗性dll4结合蛋白 | |
| JP2023002615A5 (enExample) | ||
| JP2016529882A5 (enExample) | ||
| JP2018183173A5 (enExample) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| EP3634998B1 (en) | Anti-cd3 epsilon antibodies | |
| WO2014089209A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins | |
| CN102655880A (zh) | Il-1结合蛋白 | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2018531219A (ja) | Ｐｄ−ｌ１抗体 | |
| KR20110040886A (ko) | 프로스타글란딘 ｅ2 결합 단백질 및 이의 용도 | |
| KR20110110349A (ko) | Ｉｌ-1 결합 단백질 | |
| EP2970457A2 (en) | Dual specific binding proteins directed against tnf | |
| TW201307388A (zh) | Ｉｌ－１結合蛋白 | |
| WO2013157105A1 (ja) | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 | |
| JP2017507131A5 (enExample) | ||
| RU2005121669A (ru) | Анти-nogo антитела ("11с7") и их фармацевтическое использование | |
| JPWO2022111425A5 (enExample) | ||
| AU2024255174A1 (en) | Methods of treating lymphoma with bispecific antibodies against cd3 and cd20 | |
| JPWO2023138551A5 (enExample) | ||
| WO2022238459A1 (en) | New humanized anti-vegfc antibodies and uses thereof |